文献速递白血病

伊诺妥珠单抗奥唑米星治疗儿童极高危首次复发B细胞急性淋巴细胞白血病:ITCC-059多中心单臂2期试验

Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial.
PubMed 文献 · Lancet Haematol · 2026-06-15

ITCC-059研究评估伊诺妥珠单抗奥唑米星单药治疗儿童极高危首次复发B细胞急性淋巴细胞白血病的活性与安全性。在可评估的31例患者中,总缓解率为71%(80% CI 58-82),所有患者均出现3-4级血液学毒性,无治疗相关死亡。

要点

  • 伊诺妥珠单抗奥唑米星在儿童极高危首次复发B-ALL中总缓解率达71%。
  • 常见3-4级非血液学不良事件包括发热性中性粒细胞减少和转氨酶升高。
  • 移植后患者中4例(17%)发生肝窦阻塞综合征,经去纤苷干预后均缓解。

核心结论

  • 伊诺妥珠单抗奥唑米星作为儿童极高危首次复发B-ALL的再诱导治疗显示出高活性,且毒性特征良好,无治疗相关死亡。

研究设计与样本

  • ITCC-059为多中心、国际、单臂、1-2期试验,本次分析为新增第3队列。
  • 入组37例年龄>1岁且<18岁、CD22阳性极高危首次复发B-ALL患者,接受伊诺妥珠单抗奥唑米星静脉给药。
  • 主要终点为总缓解率,定义为完全缓解、血小板未完全恢复的完全缓解和血细胞未恢复的完全缓解的最佳缓解合计率。

主要发现

  • 在最初31例可评估患者中,22例缓解,总缓解率71%(80% CI 58-82)。
  • 所有患者至少出现一项3-4级血液学实验室异常,最常见为中性粒细胞减少(35/37,95%)和血小板减少(31/37,84%)。
  • 严重不良事件发生于17例(46%)患者,无治疗相关死亡。
  • 23例移植患者中4例(17%)发生肝窦阻塞综合征,经去纤苷干预后均缓解。

关键数值与推荐

  • 极高危复发定义为初诊后18个月内发生的孤立骨髓或联合复发,或具有细胞遗传学或分子学高危特征(KTM2A::AFF1、TCF3::PBX1、TCF3::HLF、低二倍体、TP53mut/del)。

临床怎么用

  • 对于儿童极高危首次复发B-ALL,伊诺妥珠单抗奥唑米星可作为再诱导治疗选择,需密切监测血液学毒性和肝窦阻塞综合征。

局限性

  • 单臂设计,样本量较小,因招募缓慢修订样本量,随访仍在进行中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Children with very high-risk first relapse of B-cell acute lymphoblastic leukaemia have very poor outcomes with conventional chemotherapy. Inotuzumab ozogamicin has shown high antitumoral activity in second or higher relapsed or refractory B-cell acute lymphoblastic leukaemia. We aimed to evaluate the preliminary activity of inotuzumab ozogamicin single-agent in children with very high risk first B-cell acute lymphoblastic leukaemia relapse. METHODS: ITCC-059 was a multicentre, international, single-arm, phase 1-2 trial, designed to identify the recommended dose of inotuzumab ozogamicin (as monotherapy or with chemotherapy) for paediatric patients with relapsed or refractory CD22-positive acute lymphoblastic leukaemia, as previously reported, and to evaluate its activity and safety. An amendment to the original trial (April 26, 2021) introduced a third cohort, which enrolled patients at 20 hospitals across 12 countries, to evaluate the activity and safety of inotuzumab ozogamicin in children older than 1 year and younger than 18 years with CD22-positive very high risk first B-cell acute lymphoblastic leukaemia relapse and with a performance level of Karnofsky greater than 60% (for patients older than 16 years) or Lansky greater than 60% (for patients aged 16 years or younger). Very high risk relapse was defined as isolated bone marrow or combined relapse occurring less than 18 months after initial diagnosis or with cytogenetic or molecular high-risk characteristics (KTM2A::AFF1, TCF3::PBX1, TCF3::HLF, hypodiploidy, TP53mut/del). Patients were treated with intravenous inotuzumab ozogamicin at 1·8 mg/m2 in cycle 1 (0·8 mg/m2 on day 1, 0·5 mg/m2 on day 8, and 0·5 mg/m2 on day 15). Subsequent inotuzumab ozogamicin cycles were given to responding patients at a dose of 1·5 mg/m2 per cycle (0·5 mg/m2 on day 1, 0·5 mg/m2 on day 8, and 0·5 mg/m2 on day 15). A maximum of 6 cycles of inotuzumab ozogamicin were allowed. The primary endpoint for the phase 2 study for cohort 3 was the overall response rate, defined as the combined rate of patients with complete remission, complete remission with insufficient platelet recovery, and complete remission without recovery of counts as best response. Due to slow recruitment, the statistical design was amended to reduce the sample size. Recruitment continued until the amendment was approved by the competent authority (Feb 11, 2025), therefore response analysis for the primary endpoint was conducted only for the initial population that satisfied the amended minimum sample size. Safety outcomes were analysed in all patients who received at least one dose of the study drug and completed a baseline assessment and at least one post-baseline disease assessment. This trial is registered with the European Clinical Trials Information System, 2023-504694-20-00, and EudraCT, 2016-000227-71. Enrolment for cohort 3 of the study is complete, but follow-up is ongoing. FINDINGS: Between April 26, 2021, and Feb 11, 2025, 45 patients were screened for inclusion. Eight patients were excluded and 37 patients were enrolled and received treatment. Median age was 11 years (IQR 4-15); 22 (59%) of 37 patients were male and 15 (41%) were female. Among the first 31 enrolled patients (minimal amended sample size), 22 responded after treatment with inotuzumab ozogamicin (overall response rate 71%, 80% CI 58-82). All patients had at least one grade 3-4 haematologic laboratory test abnormality, with neutropenia (35 [95%] of 37 patients) and thrombocytopenia (31 patients [84%]), being the most common. The most common non-haematological grade 3-4 adverse events were febrile neutropenia (11 [30%] of 37 patients), infections (eight patients [22%], including one case of grade 5 lung infection), aspartate aminotransferase elevation (12 patients [32%]), and alanine aminotransferase elevation (ten patients [27%]). Serious adverse events occurred in 17 patients (46%). No treatment-related deaths occurred. Sinusoidal-obstructive-syndrome cases occurred in four (17%) of 23 transplanted patients, all of which resolved after intervention with defibrotide. INTERPRETATION: Inotuzumab ozogamicin showed high activity as reinduction treatment in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse and a favourable toxicity profile with no treatment-related deaths. FUNDING: Pfizer.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Peccatori N, Locatelli F, Ammerlaan ACJ, et al. Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2026. PMID: 42296977. doi:10.1016/S2352-3026(26)00104-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。